RegeneRX Biopharmaceuticals Inc. : RegeneRx Receives Orphan Drug Designation for Tß4 in the Treatment of Neurotrophic Keratopathy

ROCKVILLE, Md.--(BUSINESS WIRE)--Jan. 3, 2014-- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (T